Christoph West­phal finds the ex­it at his lat­est biotech cre­ation — af­ter the stock cratered

High-pro­file Boston biotech fi­nancier Christoph West­phal is leav­ing the helm of his lat­est biotech flop.

A lit­tle more than two years af­ter de­but­ing their IPO with a $16 share price, tiny Flex Phar­ma $FLKS an­nounced that se­r­i­al en­tre­pre­neur West­phal is hand­ing the lead role to R&D chief William McVicar, at least on an in­ter­im ba­sis, and stay­ing on as chair­man.

McVicar was re­cruit­ed to Flex two months ago. Its shares closed Mon­day at $3.43, just a shrunk­en re­flec­tion of its one-time high.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.